/

Società

Ac

Non verificato

Acurx Pharmaceuticals, Inc.

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaSanitàStart-up

3 comunicati stampa

Guarda tutti i comunicati

03/03/2025

Farmaceutica

Sanità

Biologia

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Fonte

Acurx Pharmaceuticals, Inc.

Emittente

1.00

0

24/02/2025

Farmaceutica

Sanità

Biologia

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Fonte

Acurx Pharmaceuticals, Inc.

Emittente

1.00

0

20/11/2024

Farmaceutica

Sanità

Economia

Start-up

Biologia

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Fonte

Acurx Pharmaceuticals, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0